View all news

University of Michigan Hospitals and Health Centers Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology

03/12/2008

Conversion helps U-M Hospitals and Health Centers, named one of America's best

hospitals by U.S. News & World Report, make clinical practice changes to improve patient safety

IRVINE, Calif., March 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced the completion of the University of Michigan (U-M) Hospitals and Health Centers system-wide implementation of Masimo SET pulse oximetry. Leaders at the institution cited superior clinical performance as the chief reason for conversion to Masimo SET as their standard of care for precise, continuous SpO2 monitoring.

Kevin K. Tremper, MD, Chairman of Anesthesiology at the U-M Hospitals and Health Centers, said, "Our evaluations of Masimo SET alongside other pulse oximetry technologies provided clinical staff with the opportunity to objectively appraise the performance of each of these pulse oximetry devices and we found the Masimo device to be superior."

Nationally recognized as one of the top healthcare organizations in the country and one of only 18 hospitals included in the U.S. News & World Report Best Hospitals Honor Roll, the U-M Hospitals and Health Centers is a 913-bed healthcare system encompassing three hospitals -- University Hospital, C.S. Mott Children's Hospital and Women's Hospital -- in addition to more than 30 health centers and 120 outpatient clinics.

Unlike conventional pulse oximeters, Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry is new-generation technology that uses sophisticated signal processing technologies, including parallel engines and adaptive filters, to deliver accurate and reliable SpO2 and pulse rate measurements when conventional pulse oximetry technologies don't. As a result, Masimo SET provides the greatest sensitivity (ability to detect true positives) with the greatest specificity (ability to reject false positives). By delivering meaningful alarms and alerts that can be trusted to reflect a patient's true oxygenation status, clinicians can maximize their efficiency by concentrating on caring for their patients, rather than chasing false alarms.

The sensitivity and reliability of Masimo SET pulse oximetry technology can also provide an effective solution to address the clinical concerns associated with properly monitoring at-risk post-operative patients. Rising acuity levels -- due predominately to aggressive postoperative pain management with patient-controlled analgesia (PCA) pumps and increased co-morbidities at admission -- have dramatically increased incidents of avoidable adverse and sentinel events (events resulting in death or serious physical injury). In addition, undiagnosed Obstructive Sleep Apnea (OSA) can place patients at considerable respiratory risk as pain medications typically suppress the natural breathing reflex during apneic episodes. These clinical realities have significantly impacted the way in which clinicians deliver care.

"As a result of our new Masimo SET pulse oximetry capabilities, we have implemented a policy in which all patients receiving intravenous opioids for post-operative pain are monitored with Masimo SET oximeters networked to our nurse paging system," said Dr. Tremper. "We have found that this clinical practice change provides a workable solution to a challenging national clinical problem and, in addition to being well-received by our nursing staff, we feel it has improved patient safety within the U-M Health System. We are hoping to document and share our efforts in academic publications throughout the next year."

By making the conversion to Masimo, U-M Hospitals and Health Centers joins other top hospitals in the United States -- including four of the top five, as listed on the U.S. News & World Report Honor Roll -- that have all adopted Masimo SET as their primary pulse oximetry platform. More than 100 independent and objective studies demonstrate that Masimo SET provides the most trustworthy SpO2 readings even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. These studies have shown that Masimo SET delivers improvements in outcomes, safety and efficiency.

Joe E. Kiani, CEO of Masimo, stated, "University of Michigan Hospitals and Health Centers provides numerous local and statewide community health programs and services that enable healthcare access for all. This system-wide conversion and standardization to Masimo SET pulse oximetry is an example of U-M's commitment to advancing patient care and safety for all of its patients system-wide. We are delighted to be the pulse oximetry standard for U-M and their patients and are proud to provide a solution that supported their clinical practice change to help keep their post-operative patients monitored and safe."

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)) and oxygen content (SpOC(TM)) (pending FDA clearance), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and pleth variability index (PVI(TM)), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Forward Looking Statements

This press release may include forward-looking statements. These forward-looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control, including: risks related to our assumption that U-M's standardization to Masimo technologies will serve to provide substantially increased revenues for the company, risks related to our assumption that Masimo SET and Masimo Rainbow SET will deliver a sufficient level of clinical improvement over alternative pulse oximetry and patient monitoring systems to allow for rapid adoption of the technology, risks related to our assumption that Masimo SET pulse oximetry technology provides an effective solution to address the clinical concerns associated with properly monitoring at-risk post-operative patients and that this solution will lead to increased adoption of Masimo SET technology for monitoring such patients, and risks related to our assumptions regarding the timing or commercial availability of SpHb and SpOC, and will be timely cleared, if ever, by appropriate regulatory bodies, as well as other factors discussed in the "Risk Factors" section of our annual report on Form 10-K for the year ended December 29, 2007, filed with the Securities and Exchange Commission on March 4, 2008. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward- looking statements or the risk factors contained in our annual report on Form 10-K for the year ended December 29, 2007, whether as a result of new information, future events or otherwise, except as may be required under the federal securities laws.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, and Pulse CO-Oximeters are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo

CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348

Web site: http://www.masimo.com

Multimedia Files:

Categories: Press Releases
View all news